关于内血管模型和机械取栓导航的有效性指标的立场声明，代表人工智能辅助机器人取栓利益相关者工作组（START）
A Position Statement on Endovascular Models and Effectiveness Metrics for Mechanical Thrombectomy Navigation, on behalf of the Stakeholder Taskforce for AI-assisted Robotic Thrombectomy (START)
AI总结：
本文旨在建立共识框架，开发和验证人工智能辅助机器人用于取栓，标准化有效性指标并定义参考测试环境，以提升地理多样性人群的及时取栓访问。
摘要：
尽管我们在对抗传染病和癌症方面取得进展，21世纪中叶的主要医疗挑战将是中风发病率的上升。大血管闭塞尤其具有破坏性，但有效的治疗（需在几小时内实施以获得最佳结果）受限于地理因素。为改善地理多样性人群的及时取栓访问，部署机器人手术系统是一个解决方案。人工智能（AI）辅助可能有助于提升操作员在这一新兴治疗输送方法中的技能。我们的目标是建立共识框架，以开发和验证AI辅助机器人用于取栓。目标包括标准化有效性指标，并在计算机模拟、体外、体外和体内环境中定义参考测试环境。为此，我们召集了神经介入、机器人、数据科学、健康经济学、政策、统计学和患者倡导领域的专家。通过孵化器日、德尔菲过程和最终立场声明建立共识。我们发现，四个基本测试环境各有不同的验证作用。现实要求各异：更简单的测试环境应包括与导丝和导管兼容的现实血管解剖结构，而标准测试环境应包含可变形血管。更高级的测试环境应包括血流、脉动性和疾病特征。有效性指标分为两类：一类用于计算机模拟、体外和体外阶段，聚焦于技术导航；另一类用于体内阶段，聚焦于临床结果。患者安全是该技术开发的核心。目前需要的一项患者安全任务是将体外测量与体内并发症相关联。
英文摘要：
While we are making progress in overcoming infectious diseases and cancer; one of the major medical challenges of the mid-21st century will be the rising prevalence of stroke. Large vessels occlusions are especially debilitating, yet effective treatment (needed within hours to achieve best outcomes) remains limited due to geography. One solution for improving timely access to mechanical thrombectomy in geographically diverse populations is the deployment of robotic surgical systems. Artificial intelligence (AI) assistance may enable the upskilling of operators in this emerging therapeutic delivery approach. Our aim was to establish consensus frameworks for developing and validating AI-assisted robots for thrombectomy. Objectives included standardizing effectiveness metrics and defining reference testbeds across in silico, in vitro, ex vivo, and in vivo environments. To achieve this, we convened experts in neurointervention, robotics, data science, health economics, policy, statistics, and patient advocacy. Consensus was built through an incubator day, a Delphi process, and a final Position Statement. We identified that the four essential testbed environments each had distinct validation roles. Realism requirements vary: simpler testbeds should include realistic vessel anatomy compatible with guidewire and catheter use, while standard testbeds should incorporate deformable vessels. More advanced testbeds should include blood flow, pulsatility, and disease features. There are two macro-classes of effectiveness metrics: one for in silico, in vitro, and ex vivo stages focusing on technical navigation, and another for in vivo stages, focused on clinical outcomes. Patient safety is central to this technology's development. One requisite patient safety task needed now is to correlate in vitro measurements to in vivo complications.
机构、总结、中文摘要均由AI分析而来，可能存在错误，请以论文正文为准。
